San Francisco Business Times -- A BioMarin Pharmaceutical Inc. subsidiary is returning its rights to Riquent, a drug that failed to treat a lupus-related condition, to La Jolla Pharmaceutical Co.
San Francisco Business Times -- A BioMarin Pharmaceutical Inc. subsidiary is returning its rights to Riquent, a drug that failed to treat a lupus-related condition, to La Jolla Pharmaceutical Co.
